Eno and Biochemistry signed an agreement on the joint listing of Osteoarthritis treatment agent SI-613 in Korea

Shisium Corporation (Headquarters: Tokyo, CEO: Naito Qingfu, "Aoshi") and Biochemical Industry Co., Ltd. (Headquarters: Tokyo, President: Mito Jian, "Biochemistry") recently announced that the two companies have signed a joint listing agreement in South Korea on the biochemical pioneer osteoarthritis treatment SI-613 (bichlorofenate combined with sodium hyalurogenic acid). This is the second country to conclude a joint listing agreement since self-defense materials and biochemicals signed an agreement on the joint development and joint listing of SI-613 in China on April 1, 2020.Under the agreement, Eisai Korea Inc., a subsidiary of Eisai Korea Inc., will obtain the exclusive listing rights of SI-613 in Korea and apply for its manufacturing and listing license. Upon approval, Biochemicals will supply products to Wesser, which will be responsible for distribution. The company will make an advance payment to Biochemistry and reach the sales milestone.Osteoarthritis is a disease caused by cartilage damage to joints caused by aging and other factors, causing inflammation and pain that can lead to a decline in quality of life (QOL). Knee osteoarthritis is one of the most common cases of the disease, with an estimated 3.2 million people living with knee osteoarthritis in South Korea. It is expected that this number will continue to increase as the population ages.SI-613 is a chemical combination of hyaluric acid and bichlorofenic acid (an anti-inflammatory drug) using its proprietary drug binding technology. This substance has the pain-relieving and anti-inflammatory effect of bichlorofenic acid, in addition to the joint function improvement effect of sodium hyalurogenic acid, but also aims to play a slow release effect through the release system x3. Therefore, SI-613 is expected to quickly and continuously reduce pain and inflammation associated with osteoarthritis.Under the agreement, Iso is designed to meet the unseeded medical needs of patients with knee osteoarthritis through the knowledge and network gained through its Korean operations. Biochemical will seek to maximize the value of SI-613 in Korea by utilizing Theo's Korean business base.Through the commercialization of SI-613, the two companies will offer new treatments for knee osteoarthritis in South Korea to promote improved QOL in patients.1
. About SI-613 SI-613 is a chemical combination of hyalurinoic acid and bichlorofenic acid (an anti-inflammatory drug) using its unique drug binding technology. This substance has the pain-relieving and anti-inflammatory effect of bichlorofenic acid, in addition to the joint function improvement effect of sodium hyalurogenic acid, but also aims to play a slow release effect through the release system x3. SI-613 is expected to quickly and continuously reduce pain and inflammation associated with osteoarthritis, such as the knee. In addition, the risk of systemic exposure to biclofenic acid and adverse reactions to systemic drugs is considered low due to the direct administration of it directly into the joint cavity by injection.On January 6, 2020, Biochemistry submitted an application ("NDA") for approval to manufacture and market SI-613 in Japan for the treatment of osteoarthritis (knee, hip and ankle). On April 1, 2020, Wesser and Biochemical signed an agreement on si-613's joint development and listing alliance in China.2. About Asail Wesser Co., Ltd. defines the corporate mission as "we put the interests of patients and their families first and contribute to the promotion of their well-being", i.e. the concept of caring for human health (hhc). Research and development facilities, production sites and marketing affiliates around the world have a total of nearly 10,000 employees. We strive to practice the hhc concept by providing innovative products to meet the medical needs to be met, especially in the fields of oncology and neurology. As a global pharmaceutical company, our mission is to benefit patients around the world by working with key stakeholders to improve access to medicines in developing and emerging countries.3
. About Biochemical Industry Co., Ltd.Biochemical Industry Co., Ltd. is a research and development pharmaceutical company specializing in sugar science as a field of expertise. Since its inception in 1947, Biochemistry has focused on the possibilities of sugar science and has developed original and beneficial pharmaceutical products and medical devices in the field of orthopaedic and ophthalmological diseases. With a unique business model (i.e., focusing on research and development and manufacturing without an in-house drug sales department), Biochemical contributes to the health and well-being of people around the world by working with companies with strengths in specific countries and product areas. (

): 1: For the alded data with the number of patients with knee osteoarthritis Vital Data - Statistical Korea Information Service, URL: changes in the number of patients - Healthcare Bigdata Hub, URL:s2: Sustained release is a gradual release of the active pharmaceutical ingredients of a drug to achieve a sustained therapeutic effect.*3: Drug delivery system (DDS) is a technology for the controlled release, targeting, and absorption improvement of drugs.